| In PamGene's experience |
| Our retrospective collaborative studies on clinical sample collections and our prospective work in the ongoing clinical trials are only possible because of the support of many Medical Oncologists. They believe that measuring kinase activities in patient samples, preferably cells involved in the disease such as cancer cells, will help to predict and monitor the effects of kinase inhibitors or biotherapeutics targeting cellular receptors and pathways such as EGFR, VGEFR or PDGFR. |